ACXP (Acurx Pharmaceuticals) Current Accrued Expense : $2.47 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Acurx Pharmaceuticals Current Accrued Expense?

Acurx Pharmaceuticals's Current Accrued Expense for the quarter that ended in Mar. 2025 was $2.47 Mil.

Acurx Pharmaceuticals's quarterly Current Accrued Expense declined from Sep. 2024 ($3.05 Mil) to Dec. 2024 ($2.70 Mil) and declined from Dec. 2024 ($2.70 Mil) to Mar. 2025 ($2.47 Mil).

Acurx Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2022 ($1.49 Mil) to Dec. 2023 ($2.32 Mil) and increased from Dec. 2023 ($2.32 Mil) to Dec. 2024 ($2.70 Mil).

Acurx Pharmaceuticals Current Accrued Expense Historical Data

The historical data trend for Acurx Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acurx Pharmaceuticals Current Accrued Expense Chart

Acurx Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

Get a 7-Day Free Trial

0.14

0.27

1.49

2.32

2.70

Acurx Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Accrued Expense	Get a 7-Day Free Trial															3.08	3.10	3.05	2.70	2.47

Acurx Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Acurx Pharmaceuticals Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Acurx Pharmaceuticals's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Acurx Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acurx Pharmaceuticals Inc (NAS:ACXP) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

3ZO:Germany

Address

259 Liberty Avenue, Staten Island, NY, USA, 10305

Website

https://www.acurxpharma.com

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.

Executives

Joseph C Scodari	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
David P Luci	director, 10 percent owner, officer: President and CEO
Robert J Deluccia	director, 10 percent owner	40 WASHINGTON STREET, SUITE 220, WELLESLEY HILLS MA 02481
Jack H Dean	director	C/O RESEARCH PHARMACEUTICAL SERVICES,INC, 520 VIRGINIA DRIVE, FORT WASHINGTON PA 19034
Carl Sailer	director	4 GREENBRIAR LANE, MONTVALE NJ 07645
James J. Donohue	director	C/O ACURX PHARMACEUTICALS, INC., 259 LIBERTY AVENUE, STATEN ISLAND NY 10305
Thomas L Harrison	director
Robert G. Shawah	officer: Chief Financial Officer	C/O DIPEXIUM PHARMACEUTICALS, LLC, 74 BROAD STREET, NEW YORK NY 10004